logo
logo
TKNO stock ticker logo

Alpha Teknova, Inc.

NASDAQ•TKNO
CEO: Mr. Stephen Gunstream
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2021-06-25
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Contact Information
2451 Bert Dr., Hollister, CA, 95023, United States
831-637-1100
www.teknova.com
Market Cap
$118.30M
P/E (TTM)
-6.9
37.5
Dividend Yield
--
52W High
$7.48
52W Low
$1.91
52W Range
5%
Rank48Top 64.4%
3.3
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$9.98M+0.00%
4-Quarter Trend

EPS

-$0.09+0.00%
4-Quarter Trend

FCF

-$710.00K+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth Achieved Revenue reached $40.520M, increasing 7.4% from $37.745M in 2024, driven by Lab Essentials segment growth.
Gross Margin Expansion Gross profit increased 85.9% to $13.441M; margin improved significantly to 33.2% from 19.2% reported.
Net Loss Reduction Net loss reduced by $9.486M to $(17.259)M, reflecting a 35.5% improvement in overall operating results.
Positive Investing Cash Flow Net cash provided by investing activities was $10.700M, resulting from $29.000M in short-term investment maturities.

Risk Factors

Historical Losses Persist Past operating losses incurred; future profitability uncertain if revenue growth fails to offset increasing operating expenses.
Supply Chain Disruption Risk Supply chain disruption from natural disasters or catastrophic events could negatively affect production, delivery, and product demand.
Customer Relationship Reliance Reliance on customer relationships; termination of major orders could cause temporary or permanent revenue loss.
Uncertain Future Capital Needs Future capital needs are uncertain; financing may be required but securing favorable terms is not assured.

Outlook

Deepen Customer Workflow Integration Strategy focuses on increasing integration of custom and GMP products into customer development workflows for sustained growth.
Selective Geographic Expansion Plan to expand geographic reach outside the U.S., targeting select European markets with local supply gaps.
Growth in Therapeutic Modalities Expect growth driven by continued R&D investment in cell/gene therapy, mRNA, and molecular diagnostics markets.
Infrastructure Investment Commit to operational excellence via infrastructure investment to increase capacity and reduce custom product turnaround times.

Peer Comparison

Revenue (TTM)

NEO stock ticker logoNEO
$727.33M
+10.1%
IRWD stock ticker logoIRWD
$296.15M
-15.7%
CGC stock ticker logoCGC
$278.39M
+0.6%

Gross Margin (Latest Quarter)

PRQR stock ticker logoPRQR
100.0%
+0.0pp
ACIU stock ticker logoACIU
100.0%
+0.0pp
IRWD stock ticker logoIRWD
99.0%
+32.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
IRWD$588.90M24.5-10.0%53.6%
CGC$535.10M-1.5-52.9%23.1%
IMMP$406.25M-6.8-69.2%0.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.6%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data